PF-06372865 in Subjects With Photosensitive Epilepsy

• Status: Completed
• Trial end date: 2017-02-07
• Target enrollment: 0
• Participant gender: All

Summary

PF-06372865 in subjects with photosensitive epilepsy

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer
• Treatments: Lorazepam; PF-06372865

Criteria

Inclusion Criteria:

• A diagnosis and history of photoparoxysmal response on electroencephalogram (EEG) with or without a diagnosis of epilepsy for which subjects are taking up to 0 - 2 concomitant antiepileptic drugs.

• Subjects currently taking antiepileptic drug(s) to be on a stable dose for 4 weeks prior to Screening Visit.

• A minimum average standardized photosensitive range (SPR) across all screening timepoints of 4 in the most sensitive eye condition and a non-zero average in at least one other eye condition.

Exclusion Criteria:

• Subjects with a history of status epilepticus.

• Subjects who have experienced a generalized tonic-clonic convulsion in the past 6 months, at the time of the initial screening visit.